Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06686121 · ClinicalTrials.gov registry record · Phase 3

Improving Mobility After Revascularization in Peripheral Artery Disease

A Phase 3 study of Peripheral Artery Disease and Mobility Limitation, sponsored by Northwestern University.

Recruiting
Registry status
Phase 3
Development phase
386
Enrollment target
7
Study locations

NCT06686121 is a Phase 3 study of Peripheral Artery Disease and Mobility Limitation that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 386 participants, above the 119-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (224% higher). The trial reports 7 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06686121, a Phase 3 study of Peripheral Artery Disease and Mobility Limitation, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
Phase 3
Development phase
386 participants
Enrollment target
7
Study locations

Study Summary

Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD. Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).

Interventions

  • BEHAVIORAL Attention Control
  • BEHAVIORAL Home Based Exercise
  • DRUG Nitrate Rich Beetroot Juice
  • DRUG Placebo Beetroot Juice Without Nitrate

Study Locations (7)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago
  • University of Chicago - Chicago

Arizona

  • University of Arizona - Tucson

California

  • Rancho Research Institute - Downey

Georgia

  • Emory University School of Medicine - Atlanta

New Hampshire

  • Dartmouth Hitchcock Medical Center - Lebanon

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 386 participants
Start Date 2025-08-04
Est. Completion 2032-08-01
Phase Phase 3

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT06686121

The ClinicalTrials.gov registry entry for NCT06686121 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 119-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (224% higher). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 4 interventions - of which Attention Control is the first listed.

NCT06686121 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT06686121 about?

NCT06686121 is a clinical study titled "Improving Mobility After Revascularization in Peripheral Artery Disease". Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators...

What is the current status of trial NCT06686121?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2025-08-04. Estimated completion is 2032-08-01.

What conditions does trial NCT06686121 study?

This clinical trial studies the following conditions: Peripheral Artery Disease, Mobility Limitation, Peripheral Vascular Disease, Intermittent Claudication, Revascularization.

What interventions are being tested in trial NCT06686121?

The interventions under investigation include: Attention Control (BEHAVIORAL), Home Based Exercise (BEHAVIORAL), Nitrate Rich Beetroot Juice (DRUG), Placebo Beetroot Juice Without Nitrate (DRUG).

Who is sponsoring clinical trial NCT06686121?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06686121 being conducted?

This trial has 7 study locations across Arizona, California, Georgia, Illinois, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.